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Since December 2009, mumps incidence has increased 
in the Netherlands. As of 20 April 2010, 172 cases have 
been notified on the basis of laboratory confirmation 
or linkage to a laboratory-confirmed case. Of these, 
112 were students, the majority of whom had been 
vaccinated (81%). Although outbreaks in vaccinated 
populations have been described before, risk factors 
for exposure and susceptibility, and dose-dependent 
vaccine effectiveness in a student population of this 
nature are relatively unknown. 
Background 
Mumps has been a notifiable disease in the Netherlands 
since 2009. Notification criteria include at least one 
related symptom (acute onset of painful swelling of 
the parotid or other salivary glands, orchitis or men-
ingitis) and laboratory confirmation of infection or an 
epidemiological link to a laboratory-confirmed case [1]. 
The measles-mumps-rubella (MMR) vaccine containing 
the Jeryl Lynn mumps virus strain was introduced in 
the Netherlands in 1987. Vaccination is recommended, 
with a two dose schedule at the age of 14 months and 
nine years. In 2007 and 2009, an epidemic (genotype 
D) occurred in a socio-geographically clustered, Dutch 
reformed protestant community with low vaccination 
coverage [2]. Nationally however, vaccine coverage 
with two doses has been consistently above 93% [3]. 
Despite this, an outbreak of mumps occurred among 
vaccinated national and international students at a 
particular school in 2004 [4]. A resurgence of mumps 
has been observed in vaccinated populations in coun-
tries worldwide since 2004 [5]. 
Descriptive epidemiology
In the 11 months from January to November 2009, 65 
cases of mumps were reported to the National Institute 
for Public Health and Environment (RIVM) in the 
Netherlands. Between 1 December 2009 and 20 April 
2010, 172 notifications of mumps cases were received 
(Figure 1), of whom 24% became ill in late February 
(week 11) 2010. Seventy-nine of the cases were from 
the Municipal Health Service (MHS) Zuid-Holland West 
(including the city of Delft), 44 were from MHS Hollands-
Midden (including the city of Leiden) and accounted for 
the majority of cases in week 11, 11 were reported in 
MHS Utrecht, and an additional 38 cases were reported 
from other regions across the Netherlands. The median 
age was 21 years (range: four to 46 years) and 58% 
(n=99) were male. Most of the patients had mild symp-
toms, but 14 (9%) reported some complication, which 
in 12 cases was orchitis (12% of men). One person was 
hospitalised for one night due to severe symptoms but 
had no complications. Routinely collected notification 
data revealed that a large proportion of cases (n=112, 
65%) were students. A further 11 cases were contacts 
of students. 
Twenty-seven student-cases (24% of cases) reported 
attending a student party (attended by over 2,000 
Figure 1
Mumps cases by week of onset of illness, the Netherlands, 
December 2009–April 2010 (n=172)
MHS: Municipal Health Service.
Report date: 20 April 2010.
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students) held in mid-February (week 8) over four days 
and nights in a building of the Leiden student’s asso-
ciation. The students suspected this to be the source of 
infection. Given the incubation period of mumps is typ-
ically 16 to 18 days, this would coincide with the surge 
in cases seen in week 11 in MHS Hollands-Midden. 
Some attended the party for one night only (mainly 
students from Delft and Utrecht), but the majority from 
Leiden attended for three or four days and nights in 
succession. An outbreak investigation into risk factors 
for acquisition of mumps by the MHS in Leiden, Delft 
and Utrecht is currently underway in collaboration with 
the Centre for Infectious Disease Control of RIVM. 
Microbiological findings
The clinical diagnosis of notified cases was laboratory-
confirmed by at least one method in 46% of cases 
(n=79): by detection of a mumps-specific IgM anti-
body response in 20% of cases (n=32), by detection 
of mumps virus RNA in 30% (n=48), and/or by cultiva-
tion of mumps virus in 10% (n=16). Where there was 
no laboratory confirmation, an epidemiological link to 
a laboratory-confirmed case was established in 45% of 
cases (n=78). Five cases did not meet notification cri-
teria because they were linked epidemiologically to an 
index case, but laboratory confirmation of that index 
case was not established at the time of notification. 
The remaining ten cases reportedly met the notification 
Figure 2
Mumps cases by age and vaccination status, the Netherlands, December 2009–April 2010 (n=172)
Report date: 20 April 2010.
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Table 
Vaccination status of cases reported as students and others, The Netherlands, December 2009–April 2010 (n=164) 
Vaccination status of respondents
Not reported to be students Reported as students Total
n % n % n %
At least one dose 29 50 85 81 114 70
1 dose 8 14 6 6 14 9
2 doses 21 36 77 73 98 60
3 doses 0 0 2 2 2 1
Vaccinated with unknown number of doses 0 0 1 1 1 1
Unvaccinated 29 50 20 19 49 30
Total 58 100 106 100 164 100
3www.eurosurveillance.org
criteria, but reasons for notification were incomplete or 
missing (n=6%). Genotyping of isolated mumps viruses 
revealed that the outbreak strain belonged to the G5 
lineage. 
Vaccination status of cases
Reported vaccination coverage among cases, particu-
larly among the students, was high (Table). Of the 
164 for whom vaccine status was known, 115 (70%) 
were vaccinated and 100 (61%) had received at least 
two mumps vaccinations. Among the 106 students for 
whom vaccine status was known, 85 (81%) were vac-
cinated at least once, and 79 of them were vaccinated 
at least twice.
Age and vaccination status of cases are presented in 
Figure 2. 
Discussion 
Mumps outbreaks among vaccinated populations are 
reported world-wide [5-7]. Clinical attack rates are 
generally lower in vaccinated populations (indicating 
a protective effect), but there is growing evidence of 
waning immunity over time, [8-10] leading to secondary 
vaccine failure [4,10-12]. The majority of cases in this 
outbreak were students aged 18 to 24 years, of whom 
73% had received at least two mumps vaccinations. 
The clustering of cases among students (in Leiden and 
to a lesser extent in Delft and Utrecht) suggests that 
intensive social contact during the four-day party may 
have facilitated transmission. Shared living facilities 
among members of the students’ association, and the 
close contact environment of routine college life are 
also likely contributing risk factors [13,14]. 
In accordance with recommendations from the World 
Health Organization [15], most countries now offer 
a two-dose vaccine schedule for mumps. In the 
Netherlands, all birth cohorts since 1982 have been 
offered two vaccine doses. Exceptionally, there is a 
suggestion that those born in 1986 and 1987 (now aged 
23), were offered three doses of MMR at the age of 14 
months, four years and nine years [16], but this remains 
to be confirmed. Dutch children are older when they 
receive the second vaccine dose (at age nine years) 
compared to those in the United Kingdom, the United 
States and Canada, where it is given at four to six years 
of age. Boosting of the immune response by circulat-
ing wildtype virus is unlikely as mumps has not been 
widespread in the Netherlands except for a restricted 
outbreak within the religious community a few years 
previously [2]. Primary vaccine failure is possible but 
a post-vaccination seroprevalence of 93.2% has been 
shown in children under the age of three years in the 
Netherlands [17]. In addition to the intensive social 
contact implicated in this outbreak, the fact that it 
occurred among the oldest vaccinated cohorts in the 
Netherlands who received two vaccine doses makes 
secondary vaccine failure more plausible. 
Careful investigation will be required to establish the 
relationship between increasing age on the one hand, 
and incidence rates, severity and post-exposure dis-
ease susceptibility on the other. Comparison of pre- 
and post-exposure antibody titres in a longitudinal 
study could give clues about correlates for protec-
tion against mumps virus infection, as this is not well 
understood for persons who have received two doses 
of the mumps vaccine. Antigenic differences between 
the Jeryl Lynn vaccine strain (genotype A) and the viral 
strain in this and other outbreaks (genotype G) have 
also previously been implicated [11], but recent data 
suggests a good degree of serologic cross-immunity 
between Jeryl Lynn and other genotypes [18]. 
Current outbreak response measures concentrate on 
gathering good surveillance data, and students in the 
cities affected by this mumps outbreak who are not fully 
vaccinated (i.e. with two doses of MMR) are advised 
to complete their MMR vaccination. In response to an 
ongoing outbreak in the United States among a popula-
tion of young adults (age 7-18 years) with a similar high 
vaccination coverage, public health officials in New 
York have been offering a third dose of MMR vaccine in 
some schools since January 2010 [12]. The lower inci-
dence of mumps in the Netherlands among those born 
in 1986 who may have received three vaccine doses in 
childhood is certainly interesting in this respect, but 
further investigation is required to confirm this. 
On assessment, the risk of a large national outbreak 
in the Netherlands is considered to be low because of 
high overall vaccine coverage and the clustered nature 
of student social life. Offering a third vaccine dose is 
not planned at present. With the cooperation of the 
municipal health services and the students’ associa-
tions, we intend to conduct further research to better 
understand the risk factors associated with mumps 
exposure and susceptibility, and dose-related vaccine 
effectiveness.
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